CAMBRIDGE, May 10, 2016 – TriNetX, a leader in international clinical research networks, announced today that Thomas Jefferson University signed a membership agreement to join the TriNetX network to optimize clinical trial design and advance clinical research for Jefferson programs.
Pharmaceutical researchers will gain access to Jefferson’s de-identified clinical data in real time through TriNetX’s proprietary network of healthcare institutions representing over 37 million patients in the US and Europe to support clinical study and protocol design, site selection, and patient recruitment across a range of therapeutic areas and development stages.
Jefferson will leverage the TriNetX network to drive more industry-sponsored clinical trials into its organization; enable Jefferson researchers to discover patients for investigator-initiated studies; and to collaborate with other provider research organizations.
Users of the TriNetX system can analyze patient populations with search criteria across multiple longitudinal data points, and TriNetX’s advanced analytics modules provide intelligence on which criteria have the most impact as well as the rate at which new patients present. Each data point in the TriNetX system can be traced to healthcare providers who have the ability to identify individual patients, allowing clinical researchers to develop virtual patient cohorts that can be recapitulated in real world clinical trial settings. Data in the TriNetX system is fully de-identified to the user.
“Jefferson has one of the oldest medical schools in the United States, and along with our hospital and other university schools, has been in the forefront of medical education, research, and patient care,” said Jack London, PhD., informatics core director, Sidney Kimmel Cancer Center at Jefferson and professor of cancer biology, Thomas Jefferson University. “Jefferson is proud to be the first provider live on the TriNetX network—a testament to our focus on innovation and collaboration in clinical research. Together with the other TriNetX network members, we will advance the frontiers of scientific knowledge and help bring new therapies to patients.”
“Our mission is to disrupt the clinical trial design space by unleashing the power of data that is currently locked away,” said Gadi Lachman, CEO, TriNetX. “Through our network, healthcare providers, pharmaceutical companies and contract research organizations can create strategic partnerships to improve clinical research and patient care, and we are honored to have Jefferson as part of our network. We see this collaboration agreement as a win-win for Jefferson, TriNetX, our member institutions, and ultimately patients.”
TriNetX is a worldwide clinical data network of healthcare providers, pharmaceutical companies and contract research organizations used to enhance clinical trial design and accelerate patient recruitment. TriNetX enables researchers to find the right patients at the right sites for clinical trials. For more information, visit https://open.tnxdev.com/.
+1 (857) 285-6038